14497-27-9

Basic information

• Product Name: 5-PROPYL-FURAN-2-CARBALDEHYDE
• Synonyms: ASISCHEM D29295;5-PROPYL-FURAN-2-CARBALDEHYDE;5-propyl-2-furaldehyde(SALTDATA: FREE);5-Propyl-2-furaldehyde;2-Furancarboxaldehyde, 5-propyl-
• CAS NO: 14497-27-9
• Molecular Formula: C₈H₁₀O₂
• Molecular Weight: 138.16
• Mol File: 14497-27-9.mol
• Article Data: 6

Chemical Properties

• Melting Point: 100-101 °C
• Boiling Point: 221.6 °C at 760 mmHg
• Flash Point: 76.1 °C
• Appearance: /
• Density: 1.037 g/cm³
• Vapor Pressure: 0.106mmHg at 25°C
• Refractive Index: 1.504
• CAS DataBase Reference: 5-PROPYL-FURAN-2-CARBALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-PROPYL-FURAN-2-CARBALDEHYDE(14497-27-9)
• EPA Substance Registry System: 5-PROPYL-FURAN-2-CARBALDEHYDE(14497-27-9)

Safety Data

• Hazard Codes: Xi
• Statements: 43
• Safety Statements: 36/37
• HazardClass: IRRITANT
• Hazardous Substances Data: 14497-27-9(Hazardous Substances Data)

Usage

Description

5-PROPYL-FURAN-2-CARBALDEHYDE is an organic compound characterized by its distinct chemical structure and properties. It is a derivative of furan, a heterocyclic compound with a five-membered ring containing four carbon atoms and one oxygen atom. The presence of a propyl group and a formyl group attached to the furan ring gives 5-PROPYL-FURAN-2-CARBALDEHYDE its unique characteristics and potential applications in various fields.

Uses

Used in Pharmaceutical Industry:
5-PROPYL-FURAN-2-CARBALDEHYDE is used as an inhibitor for the Hepatitis C virus NS5B polymerase. This application is significant because it helps in the development of antiviral drugs targeting the Hepatitis C virus, which is responsible for causing a severe liver infection that can lead to liver disease, cirrhosis, and even liver cancer.
The compound's ability to inhibit the NS5B polymerase, a key enzyme involved in the replication of the Hepatitis C virus, makes it a valuable candidate for the development of new therapeutic strategies against this viral infection. By targeting and inhibiting the NS5B polymerase, 5-PROPYL-FURAN-2-CARBALDEHYDE can potentially disrupt the virus's replication process, thereby reducing the viral load and helping in the treatment of Hepatitis C.

InChI:InChI=1/C8H10O2/c1-2-3-7-4-5-8(6-9)10-7/h4-6H,2-3H2,1H3

Upstream product

• 121389-55-7 tert-butyl(furan-2-ylmethoxy)dimethylsilane 
• 98-00-0 (2-furyl)methyl alcohol 
• 2386-64-3 ethylmagnesium chloride 
• 126080-78-2 2-(chloromethyl)-5-(dibutoxymethyl)furan 
• 4229-91-8 2-propylfuran 
• 1450-58-4 anti-furfuraldoxime 
• 68-12-2 N,N-dimethyl-formamide 
• 13529-27-6 2-(diethoxymethyl)furan 
• 106-94-5 propyl bromide 
• 89114-37-4 5-(n-propyl)furfuraldehyde oxime 

Downstream Products

• 83960-83-2 2-ethyl-3-oxocyclopent-1-enecarbaldehyde 

Relevant articles and documents

A flexible synthesis of the phytoprostanes B1 type I and II

(Chemical Equation Presented) Syntheses of the enantiomerically pure phytoprostanes B1 type I and II are described starting from furfural and n-propylfuran. Key steps include the preparation of the Freimanis (±)-hydroxycyclopentenone and Wittig

Design and synthesis of amino acid tethered thiazolones to screen for hepatitis C NS5B polymerase inhibitors

Background: Hepatitis C Virus (HCV) infection is one of the causes for liver cirrhosis and hepatocellular carcinoma leading to liver failure. An estimated 2-3% of the world population is chronically infected with HCV. HCV is a positive single stranded RNA virus encoding for a single polypeptide, which cleaves into structural and non-structural proteins. The non-structural (NS) proteins play critical roles in viral replication and have become the targets for HCV chemotherapy. The current treatment involves pegylated interferon-α/ribavirin-based treatment and a combination of direct-acting antivirals. NS5B is a critical enzyme for the replication of HCV RNA and is an interesting target for the screening and design of small molecule inhibitors to interfere in the HCV viral replication. Methods: Screening of a library of compounds in a replicon assay, a thiazolone derivative was identified as a NS5B enzyme inhibitor (IC50: 11 μM). Based on the structure of this lead compound, few libraries of compounds were designed and synthesized following a fragment based approach. Structural features of both peptide-based and non-peptide-based protease inhibitors such as lopinavir and tipranavir were considered while designing novel compounds. Results: Several novel protease inhibitors were designed and synthesized based on the structural fragments of lopinavir and tipranavir. This resulted in identification of compounds with thiazolone scaffold as having good anti-HCV NS5B enzyme activity. However, to improve their cellular activity, the thiazolone scaffold was then tethered with several amino acids and then screened for their anti-HCV activity which led to finding a tethered thiazolone as novel hepatitis C NS5B polymerase inhibitor with good cellular potency (EC50 = 1.2 μM). Conclusion: Systematic modification of lead compound (EC50 = 35 μM) from an enzyme assay and by tethering with a suitable amino acid improved the cellular potency of the lead compound. This resulted in a compound 18c with nearly 30 fold (EC50 = 1.2 μM) potent compound in cellular assay than the original lead compound. It’s believed that this improvement was possible because of better transport of the active compound into the cell due to its amino acid tether.

Therapeutic phenoxyalklpyridazines and intermediates therefor

Compounds of the formula STR1 wherein: R1 and R2 are independently hydrogen, halo, alkyl, alkenyl, alkoxy, hydroxy, hydroxyalkyl, hydroxyhaloalkyl, alkoxyalkyl, alkylthioalkynyl, hydroxyalkoxy, alkylthioalkyl, alkylsulfinylalkyl, alk